Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 9556958

Anesthesia control using midlatency auditory evoked potentials.

A Nayak·R J Roy
View original source ↗Export metadata ↓

Abstract

This paper shows the development of a system to control inhalation anesthetic concentration delivered to a patient based upon that patient's midlatency auditory evoked potentials (MLAEP's). It was developed and tested in dogs by determining response to the supramaximal stimulus of tail clamping. Prior to tail clamp, the MLAEP was recorded along with inhalational anesthetic concentration and classified as responders or nonresponders as determined by tail clamping. This was performed at a number of different anesthetic levels to obtain a data training set. The MLAEP's were compacted by means of discrete time wavelet transform (DTWT), and together with anesthetic concentration value, a stepwise discriminant analysis (SDA) was performed to determine those features which could separate responders from nonresponders. It was determined that only three features were necessary for this recognition. These features were then used to train a four-layer artificial neural network (ANN) to separate the responders from nonresponders. The network was tested using a separate set of data, resulting in a 93% recognition rate in the anesthetic transition zone between responders and nonresponders, and 100% recognition rate outside this zone. The anesthetic controller used this ANN combined with fuzzy logic and rule-based control. A set of ten animal experiments were performed to test the robustness of this controller. Acceptable clinical performance was obtained, showing the feasibility of this approach.

Explore related subjects

AnesthesiaAnesthesiologyAnesthetics, InhalationAnimalsComputer SimulationDiscriminant AnalysisDogsElectroencephalographyEquipment DesignEvoked Potentials, AuditoryFuzzy LogicHemodynamicsIsofluraneModels, NeurologicalMonitoring, PhysiologicNeural Networks, ComputerReaction TimeJournal ArticleResearch Support, Non-U.S. Gov'tResearch Support, U.S. Gov't, Non-P.H.S.

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A Nayak, R J Roy. 1998. Anesthesia control using midlatency auditory evoked potentials.. https://doi.org/10.1109/10.664197

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2004

The GABA-A beta3 subunit mediates anaesthesia induced by etomidate.

The i.v. agent etomidate exerts its anaesthetic actions through potentiation of gamma-aminobutyric acid-A receptors containing beta2 and beta3 subunits. It was recently shown that the beta2 subunit contributes to the sedative properties of etomidate, whereas the beta3 subunit is responsible for its anaesthetic properties. However, these studies evaluated anaesthetic effects in point mutation mice in which the effect of etomidate was decreased, but not abolished, at the beta2 subunit. Here we have used beta2 knockout mice to completely remove any contribution of the beta2 subunit to the effects of etomidate. Etomidate was equally anaesthetic in wildtype and knockout mice, thus further confirming that efficacy at the beta3 subunit only is sufficient to induce general anaesthesia.

Anesthesia↗
PubMed2004

Determination of extracellular hesperidin in blood and bile of anaesthetized rats by microdialysis with high-performance liquid chromatography: a pharmacokinetic application.

A method coupled with microdialysis technique and liquid chromatography was applied in the continuous and concurrent in vivo monitoring of extracellular hesperidin in the blood and bile of anaesthetized rats. Hesperidin was intravenously administered via the femoral vein. Sampling was achieved using two microdialysis probes, which were implanted into the jugular vein and into the bile duct. Dialysates of blood and bile were both directly injected onto the liquid chromatographic system, so no further clean-up procedures were required. Separation was performed using a reversed phase ODS-2 microbore column 150 mm x 1 mm i.d., particle size 5 microm with mobile phase of acetonitrile-0.1M ammonium acetate (30:70, v/v) at flow-rate of 0.05 ml/min. The UV detection for hesperidin was set at a wavelength of 283 nm. This method was used to determine the pharmacokinetics of hesperidin and its interaction in the presence of cyclosporin A, which is a P-glycoprotein modulator. The results indicate that the curve of area under the concentration versus time (AUC) for hesperidin in bile was significantly greater than that for hesperidin in blood at the dose of 30 mg/kg. The blood-to-bile distribution ratio (k = AUC(bile)/AUC(blood)) was 8.9 +/- 2.5 for hesperidin at 30 mg/kg. Following cyclosporin A treatment, the distribution ratio was reduced to 3.2 +/- 0.6. In conclusion, hesperidin goes through hepatobiliary elimination against the concentration gradient from blood to bile, and this hepatobiliary excretion of hesperidin may be regulated by the P-glycoprotein.

Anesthesia↗
PubMed2004

Effects of TAK-802, a novel acetylcholinesterase inhibitor, and various cholinomimetics on the urodynamic characteristics in anesthetized guinea pigs.

In the present study, we investigated the effects of cholinomimetic drugs on the urodynamic characteristics in anesthetized guinea pigs. 8-[3-[1-[(3-fluorophenyl)methyl]-4-piperidinyl]-1-oxopropyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one (TAK-802), a novel acetylcholinesterase inhibitor, (0.003-0.03 mg/kg, i.v.) increased the voided volume and the maximum flow rate without affecting either the intravesical pressure or the bladder compliance. Distigmine (0.03-0.3 mg/kg, i.v.) and neostigmine (0.01-0.1 mg/kg, i.v.), both carbamate acetylcholinesterase inhibitors, while not increasing the maximum flow rate, increased the intravesical pressure at the maximum flow rate. They also decreased the bladder compliance. Bethanechol (0.1-1 mg/kg, i.v.), a muscarinic receptor agonist, decreased the voided volume and the bladder compliance but did not affect the maximum flow rate. TAK-802 did not affect the intraurethral pressure at doses of up to 0.03 mg/kg in anesthetized guinea pigs. Distigmine increased the intraurethral pressure when administered at the dose of 0.3 mg/kg, and the effect was completely abolished by pretreatment with d-tubocurarine. These results suggest that TAK-802 reinforces the bladder-voiding functions by increasing the bladder contractility without decreasing the storage function. On the other hand, carbamate acetylcholinesterase inhibitors not only deteriorate the voiding function by inducing contraction of the external urethral sphincter muscle, resulting in increasing the urethral resistance, but also cause deterioration of the storage function. Bethanechol obviously decreased the bladder capacity, possibly due to a direct contractile effect on the detrusor smooth muscle. TAK-802 may therefore be a more useful drug than either carbamate acetylcholinesterase inhibitors or muscarinic receptor agonists in the treatment of voiding dysfunction associated with impaired detrusor contractility.

Anesthesia↗